SAGE Therapeutics (SAGE) Stock Statistics & Valuation Metrics

SAGE Therapeutics has a market cap or net worth of $429.58M. The enterprise value is $79.77M.

SAGE Therapeutics has 62,620,693 shares outstanding. The number of shares has decreased by -2.65% in one year.

SAGE Therapeutics’s return on equity (ROE) is -0.86 and return on invested capital (ROIC) is -90.66%.

The current PE Ratio of SAGE Therapeutics is -0.82. SAGE Therapeutics’s PEG ratio is 0.03.

In the last 12 months, SAGE Therapeutics had revenue of 41.24M and earned -400.67M in profits. Earnings per share was -6.59.

In the last 12 months, operating cash flow was -311.09M and capital expenditures 0.00, giving a free cash flow of -311.09M billion.

SAGE Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

SAGE Therapeutics upcoming earnings date is Aug 5, 2025, TBA Not Confirmed.

SAGE Therapeutics as a current ratio of 7.42, with Debt / Equity ratio of 2.89%

In the past 12 months, SAGE Therapeutics has paid 0.00 in taxes.

SAGE Therapeutics EV to EBITDA ratio is -0.64, with an EV/FCF ratio of -0.98.

SAGE Therapeutics has $423.85M in cash and marketable securities with $3.31M in debt, giving a net cash position of -$412.00M billion.

Gross margin is 81.37%, with operating margin of -1048.35%, and net profit margin of -971.48%.

The average price target for SAGE Therapeutics is $8.43, which is 11.43% higher than the current price. The consensus rating is Hold